Engineering services provider Acromec debuts on the Catalist

It will use the funds to fuel expansion.

Acromec, a Singapore-based company that specialises in the design and construction of facilities requiring controlled environments, launched its initial public offering (IPO) on the Catalist on April 18.

The company primarily serves the healthcare, biomedical, research and academia, and electronics sectors, and counts Singapore General Hospital, Agency for Science, Technology and Research (A*STAR), National University of Singapore, Procter & Gamble and Johnson Matthey Singapore, amongst its clients.

“With two decades of experience in the provision of integrated specialist engineering solutions within controlled environments, Acromec has built up an established track record in Singapore. Our listing on the Catalist is timely, planned at a time when we are forging ahead with strategies to scale up our operations in Singapore and also expand our horizons into the emerging ASEAN region,” said Lim Say Chin, Executive Chairman and Managing Director of Acromec.

Acromec will trade under the stock code 43F. Its listing brings the total number of companies on Catalist to 178, with a combined market capitalisation of S$9 billion.